B7-2–positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy
Open Access
- 15 August 2000
- journal article
- Published by American Society of Hematology in Blood
- Vol. 96 (4), 1274-1279
- https://doi.org/10.1182/blood.v96.4.1274
Abstract
Deficiencies in B7:CD28 costimulation are considered to be one of the major causes of the failure to generate a tumor-specific immune response. Up-regulating the expression of the B7 molecules on malignant B cells has been shown to stimulate cytotoxic T cells. Plasma cells from patients with myeloma express a tumor-specific idiotype but lack CD80 (B7-1) and have a variable expression of CD86 (B7-2). This study has identified the incidence and clinical significance of high CD86 expression on plasma cells at diagnosis and studied the ability of trimeric human CD40 ligand (huCD40LT) to up-regulate the expression of the B7 family on malignant plasma cells. CD86 expression on plasma cells was increased in 54% of the patients studied at diagnosis (n = 35) and was associated with a significantly shorter survival (median, 28 versus 57 months; χ2 = 4.6;P = .03) and a higher tumor load (patients with more than 50% bone marrow plasma cells, 47% versus 6%; χ2 = 7.2; P = .005). CD86 expression was highest on immature and primitive plasma cells (CD38++, CD45+) of both patients and controls and was associated with a CD40+, CD20+, CD19−, CD138+ phenotype. The shortened survival was associated with high CD86 only on mature (CD38++, CD45−) plasma cells (χ2 = 7.6; P = .006). There was no significant correlation between high CD86 and other known prognostic markers, including serum β2-microglobulin, serum thymidine kinase, and labeling index. The addition of huCD40LT to short-term cultures up-regulated both CD80 and CD86 expression on B cells (CD19+) and CD80 on plasma cells (CD38++), but did not up-regulate CD86 expression on plasma cells. Thus, B7-2–positive myeloma consists of a subgroup of patients with a relatively poor prognosis, and CD40LT may be useful in immunotherapy protocols because it up-regulates CD80 expression on malignant plasma cells without inducing B7-2–positive myeloma.Keywords
This publication has 33 references indexed in Scilit:
- Reciprocal Control of T Helper Cell and Dendritic Cell DifferentiationScience, 1999
- T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: Clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burdenEuropean Journal of Immunology, 1997
- The prognostic significance of T cell receptor β gene rearrangements and idiotype-reactive T cells in multiple myelomaLeukemia, 1997
- The Labelling Index of Primitive Plasma Cells Determines the Clinical Behaviour of Patients with MyelomatosisBritish Journal of Haematology, 1996
- Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production.The Journal of Experimental Medicine, 1993
- Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V TrialBritish Journal of Haematology, 1993
- Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal.The Journal of Experimental Medicine, 1993
- CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clonesNature, 1992
- Peripheral blood T lymphocytes in patients with monoclonal gammopathies: Expanded subsets as depicted by capacity to bind to autologous monoclonal immunoglobulins or reactivity with anti‐V gene‐restricted antibodiesEuropean Journal of Haematology, 1991
- A Cell Culture Model for T Lymphocyte Clonal AnergyScience, 1990